PDF herunterladen
CC BY 4.0 · World J Nucl Med 2023; 22(02): 135-139
DOI: 10.1055/s-0043-1760762
Case Report

18F-FDG Brain PET/MRI in Amyotrophic Lateral Sclerosis– Frontotemporal Spectrum Disorder (ALS-FTSD)

Faizullah Mashriqi
1   Neuroradiology Division, Department of Radiology, Northwell Health/Donald and Barbara Zucker School of Medicine, Lenox Hill Hospital, New York, United States
,
Bibhuti B. Mishra
2   Department of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institutes for Medical Research. Manhasset, New York, United States
,
Luca Giliberto
2   Department of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institutes for Medical Research. Manhasset, New York, United States
,
Ana M. Franceschi 
1   Neuroradiology Division, Department of Radiology, Northwell Health/Donald and Barbara Zucker School of Medicine, Lenox Hill Hospital, New York, United States
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal and progressive neurodegenerative disorder involving both upper and lower motor neurons. Interestingly, 15 to 41% of patients with ALS have concomitant frontotemporal dementia (FTD). Approximately, 50% of patients with ALS can copresent with a broader set of neuropsychological pathologies that do not meet FTD diagnostic criteria. This association resulted in revised and expanded criteria establishing the ALS-frontotemporal spectrum disorder (FTSD). In this case report, we review background information, epidemiology, pathophysiology, and structural and molecular imaging features of ALS-FTSD.

Keywords

amyotrophic lateral sclerosis - amyotrophic lateral sclerosis-frontotemporal spectrum disorder - 18F-FDG - PET/MRI - brain PET


Publikationsverlauf

Artikel online veröffentlicht:
01. Mai 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377 (02) 162-172
    CrossrefPubMedSuche in Google Scholar
  • 2 Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc 2018; 93 (11) 1617-1628
    CrossrefPubMedSuche in Google Scholar
  • 3 Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. Als genetics, mechanisms, and therapeutics: where are we now?. Front Neurosci 2019; 13: 1310
    CrossrefPubMedSuche in Google Scholar
  • 4 Schweitzer A, Tsiouris AJ. Amiotrophic lateral sclerosis. In: Franceschi AM, Franceschi D. eds. Hybrid PET/MR Neuroimaging: A Comprehensive Approach. Springer Nature; Switzerland: 2022. . ISBN 978–3-030–82366–5. eISBN 978–3-030–82367–2. 78–3-030–82367–2.
    CrossrefSuche in Google Scholar
  • 5 Kumfor F, Irish M, Hodges JR, Piguet O. Frontal and temporal lobe contributions to emotional enhancement of memory in behavioral-variant frontotemporal dementia and Alzheimer's disease. Front Behav Neurosci 2014; 8: 225
    CrossrefPubMedSuche in Google Scholar
  • 6 Wang Y, Spincemaille P, Liu Z. et al. Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care. J Magn Reson Imaging 2017; 46 (04) 951-971
    CrossrefPubMedSuche in Google Scholar
  • 7 Vázquez-Costa JF, Mazón M, Carreres-Polo J. et al. Brain signal intensity changes as biomarkers in amyotrophic lateral sclerosis. Acta Neurol Scand 2018; 137 (02) 262-271
    CrossrefPubMedSuche in Google Scholar
  • 8 Govind V, Sharma KR, Maudsley AA, Arheart KL, Saigal G, Sheriff S. Comprehensive evaluation of corticospinal tract metabolites in amyotrophic lateral sclerosis using whole-brain 1H MR spectroscopy. PLoS One 2012; 7 (04) e35607
    CrossrefPubMedSuche in Google Scholar
  • 9 Turner MR, Grosskreutz J, Kassubek J. et al; first Neuroimaging Symposium in ALS (NISALS). Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011; 10 (05) 400-403
    CrossrefPubMedSuche in Google Scholar
  • 10 Müller HP, Turner MR, Grosskreutz J. et al; Neuroimaging Society in ALS (NiSALS) DTI Study Group. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016; 87 (06) 570-579
    CrossrefPubMedSuche in Google Scholar
  • 11 Chew S, Atassi N. Positron emission tomography molecular imaging biomarkers for amyotrophic lateral sclerosis. Front Neurol 2019; 10: 135
    CrossrefPubMedSuche in Google Scholar
  • 12 Strong MJ, Abrahams S, Goldstein LH. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18 (3-4): 153-174
    CrossrefPubMedSuche in Google Scholar
  • 13 Marini C, Morbelli S, Cistaro A. et al. Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain 2018; 141 (08) 2272-2279
    CrossrefPubMedSuche in Google Scholar
  • 14 Van Weehaeghe D, Devrome M, Schramm G. et al. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. Eur J Nucl Med Mol Imaging 2020; 47 (11) 2681-2690
    CrossrefPubMedSuche in Google Scholar
  • 15 Lai TH, Liu RS, Yang BH. et al. Cerebral involvement in spinal and bulbar muscular atrophy (Kennedy's disease): a pilot study of PET. J Neurol Sci 2013; 335 (1-2): 139-144
    CrossrefPubMedSuche in Google Scholar
  • 16 Cabona C, Benedetti L, Delucchi S. et al. Cervical alterations in Hirayama disease: an MRI and FDG-PET combined approach. Clin Transl Imaging 2021; 9: 117-119
    CrossrefSuche in Google Scholar